Publication | Closed Access

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)

VaccinationVaccine SafetyBreast OncologyOncologyEarly Breast CancerImmunologyTherapeutic VaccinePrecision VaccinologyBreast CancerVaccine EfficacyImmunotherapyMedicineAbcsg 34